Cargando…

Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer

BACKGROUND: We address the prognostic and predictive value of KRAS, PIK3CA and BRAF mutations for clinical outcomes in response to active agents in the treatment of metastatic colorectal cancer (mCRC). METHODS: We determined KRAS, BRAF and PIK3CA mutations in tumours from 168 patients treated for mC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Souglakos, J, Philips, J, Wang, R, Marwah, S, Silver, M, Tzardi, M, Silver, J, Ogino, S, Hooshmand, S, Kwak, E, Freed, E, Meyerhardt, J A, Saridaki, Z, Georgoulias, V, Finkelstein, D, Fuchs, C S, Kulke, M H, Shivdasani, R A
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2009
Materias:	Molecular Diagnostics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2720232/ https://www.ncbi.nlm.nih.gov/pubmed/19603024 http://dx.doi.org/10.1038/sj.bjc.6605164

Ejemplares similares

BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome
por: Saridaki, Z, et al.
Publicado: (2010)

Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2011)

Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies
por: Roy, R, et al.
Publicado: (2014)

Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008)

Prognostic significance of AMP-activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer
por: Baba, Y, et al.
Publicado: (2010)

‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
por: Pallis, A G, et al.
Publicado: (2007)

Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer
por: Balgkouranidou, I, et al.
Publicado: (2014)

Hypoxia-inducible factor-1α and -2α are expressed in most rectal cancers but only hypoxia-inducible factor-1α is associated with prognosis
por: Rasheed, S, et al.
Publicado: (2009)

BRAF(V600E) protein expression and outcome from BRAF inhibitor treatment in BRAF(V600E) metastatic melanoma
por: Wilmott, J S, et al.
Publicado: (2013)

Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib
por: Beuselinck, B, et al.
Publicado: (2013)

A comparison of Ki-67 and mitotic count as prognostic markers for metastatic pancreatic and midgut neuroendocrine neoplasms
por: Khan, M S, et al.
Publicado: (2013)

miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215
por: White, N M A, et al.
Publicado: (2011)

Elevated serum CXCL16 is an independent predictor of poor survival in ovarian cancer and may reflect pro-metastatic ADAM protease activity
por: Gooden, M J M, et al.
Publicado: (2014)

Endo180 modulation by bisphosphonates and diagnostic accuracy in metastatic breast cancer
por: Palmieri, C, et al.
Publicado: (2013)

Identification of claudin-4 as a marker highly overexpressed in both primary and metastatic prostate cancer
por: Landers, K A, et al.
Publicado: (2008)

Viable circulating tumour cell detection using multiplex RNA in situ hybridisation predicts progression-free survival in metastatic breast cancer patients
por: Payne, R E, et al.
Publicado: (2012)

Glutathione S-transferase M1-null genotype as risk factor for SOS in oxaliplatin-treated patients with metastatic colorectal cancer
por: Vreuls, C P H, et al.
Publicado: (2013)

Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer
por: Baker, J B, et al.
Publicado: (2011)

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy
por: del Puerto-Nevado, L, et al.
Publicado: (2014)

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer
por: Peeters, D J E, et al.
Publicado: (2011)

CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2
por: Bedognetti, D, et al.
Publicado: (2013)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes
por: Peeters, D J E, et al.
Publicado: (2014)

KRAS, NRAS, BRAF mutation comparison of endoscopic and surgically removed primary CRC paired samples: is endoscopy biopsy material adequate for molecular evaluation?
por: Saridaki, Z, et al.
Publicado: (2015)

NT5E (CD73) is epigenetically regulated in malignant melanoma and associated with metastatic site specificity
por: Wang, H, et al.
Publicado: (2012)

Phosphorylated protein phosphatase 2A determines poor outcome in patients with metastatic colorectal cancer
por: Cristóbal, I, et al.
Publicado: (2014)

Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer
por: Chua, W, et al.
Publicado: (2009)

Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma
por: Bengochea, A, et al.
Publicado: (2008)

Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer
por: Rao, S R, et al.
Publicado: (2017)

Elevated level of inhibin-α subunit is pro-tumourigenic and pro-metastatic and associated with extracapsular spread in advanced prostate cancer
por: Balanathan, P, et al.
Publicado: (2009)

Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease
por: Zidan, J, et al.
Publicado: (2005)

Circulating insulin-like growth factor axis and the risk of pancreatic cancer in four prospective cohorts
por: Wolpin, B M, et al.
Publicado: (2007)

Characterisation of a novel cell line (CSQT-2) with high metastatic activity derived from portal vein tumour thrombus of hepatocellular carcinoma
por: Wang, T, et al.
Publicado: (2010)

Spontaneous dormancy of metastatic breast cancer cells in an all human liver microphysiologic system
por: Wheeler, S E, et al.
Publicado: (2014)

The small-nucleolar RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis
por: Gee, H E, et al.
Publicado: (2011)

Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer
por: Dotan, E, et al.
Publicado: (2012)

CD9P-1 expression correlates with the metastatic status of lung cancer, and a truncated form of CD9P-1, GS-168AT2, inhibits in vivo tumour growth
por: Guilmain, W, et al.
Publicado: (2011)

Epstein-Barr Virus latent membrane protein 1 induces Snail and epithelial–mesenchymal transition in metastatic nasopharyngeal carcinoma
por: Horikawa, T, et al.
Publicado: (2011)

Feasibility of proposed single-nucleotide polymorphisms as predictive markers for targeted regimens in metastatic colorectal cancer
por: Kim, J C, et al.
Publicado: (2013)

PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients
por: Frattini, M, et al.
Publicado: (2007)

BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection
por: Schirripa, M, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rnhcfp507dsi0vr7vnq5e24n4q